AbbVie lowers second quarter and full-year 2026 EPS guidance by $0.17 due to a $291 million R&D expense.

AbbVie updated its financial guidance for the second quarter and full-year 2026, lowering its adjusted EPS forecast to incorporate a significant research and development expense. The company noted that its second quarter results have not yet been finalized.

Key Highlights

• Full-year 2026 adjusted diluted EPS guidance was lowered to a range of $13.91 to $14.11, down from the previous range of $14.08 to $14.28.
• Second quarter 2026 adjusted diluted EPS guidance is now expected to be between $3.57 and $3.61, a reduction from the prior forecast of $3.74 to $3.78.
• The guidance revision is directly attributable to an expected $291 million pre-tax charge for acquired In-Process Research & Development (IPR&D) and milestones.